EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Study Summary

The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

Conditions

Breast Cancer

Interventions / Drugs

ctDNA MRD test

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1800 participants

Primary Completion—

Lead SponsorExact Sciences Corporation

Data Retrieved2026-04-11 04:13:38.204313+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.